Immunologic Factors

"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Biologically active substances whose activities affect or play a role in the functioning of the immune system.

Descriptor ID	D007155
MeSH Number(s)	D27.505.696.477
Concept/Terms	Immunologic Factors Immunologic Factors Immune Factors Factors, Immune Immunological Factors Factors, Immunological Factors, Immunologic Immunomodulators Immunomodulators Biological Response Modifiers Biological Response Modifiers Biomodulators Modifiers, Biological Response Response Modifiers, Biological

Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Immunologic Factors [D27.505.696.477]

Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.

Bar chart showing 134 publications over 23 distinct years, with a maximum of 12 publications in 2008 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2002	1	0	1
2004	0	1	1
2005	0	1	1
2006	0	3	3
2007	2	4	6
2008	7	5	12
2009	3	3	6
2010	6	3	9
2011	4	2	6
2012	5	1	6
2013	3	5	8
2014	5	4	9
2015	9	0	9
2016	7	5	12
2017	3	4	7
2018	4	3	7
2019	6	2	8
2020	6	2	8
2021	5	2	7
2022	0	2	2
2023	1	1	2
2024	0	3	3

Below are the most recent publications written about "Immunologic Factors" by people in Profiles.

Bril V, Berkowicz T, Szczudlik A, Nicolle MW, Bednarik J, Hon P, Vaitkus A, Vu T, Rozsa C, Magnus T, Panczel G, Toomsoo T, Pasnoor M, Mozaffar T, Freimer M, Reuner U, V?csei L, Souayah N, Levine T, Pascuzzi RM, Dalakas MC, Rivner M, Griffin R, Coll MQ, Mondou E. Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial. Muscle Nerve. 2025 Jan; 71(1):43-54.

View in: PubMed
Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Ann Intern Med. 2024 03; 177(3):343-352.

View in: PubMed
Yang R, Ko YH, Li F, Lokareddy RK, Hou CD, Kim C, Klein S, Antol?nez S, Mar?n JF, P?rez-Segura C, Jarrold MF, Zlotnick A, Hadden-Perilla JA, Cingolani G. Structural basis for nuclear import of hepatitis B virus (HBV) nucleocapsid core. Sci Adv. 2024 01 12; 10(2):eadi7606.

View in: PubMed
Miller KD, O'Connor S, Pniewski KA, Kannan T, Acosta R, Mirji G, Papp S, Hulse M, Mukha D, Hlavaty SI, Salcido KN, Bertolazzi F, Srikanth YVV, Zhao S, Wellen KE, Shinde RS, Claiborne DT, Kossenkov A, Salvino JM, Schug ZT. Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer. Nat Cancer. 2023 10; 4(10):1491-1507.

View in: PubMed
Leist TP, Cole M, Verma S, Keenan A, Le HH. A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy. Mult Scler Relat Disord. 2023 Oct; 78:104917.

View in: PubMed
Thomas S, Mercogliano G, Prendergast GC. Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment. PLoS One. 2022; 17(11):e0276910.

View in: PubMed
Nicol? E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, Cristofanilli M, Curigliano G. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022 May; 106:102395.

View in: PubMed
Dalakas MC. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. Neurol Neuroimmunol Neuroinflamm. 2022 01; 9(1).

View in: PubMed
Shields CL, Paulose SA, Yaghy A, Dalvin LA, Constantinescu AB, Lally SE, Shields JA. Ocular Surface Squamous Neoplasia Managed With Primary Interferon a2b: A Comparative Analysis of 212 Tumors in Smokers Versus Nonsmokers. Cornea. 2021 Nov 01; 40(11):1387-1394.

View in: PubMed
Fadul CE, Mao-Draayer Y, Ryan KA, Noelle RJ, Wishart HA, Channon JY, Kasper IR, Oliver B, Mielcarz DW, Kasper LH. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 11; 8(6).

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement